1The Department of Anesthesiology and Critical Care Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
2Section of Critical Care Medicine, Department of Medicine, Veterans Affairs Healthcare System and University of Miami, Miami, FL.
3Division of Pulmonary and Critical Care Medicine, Rush University Medical Center, Chicago, IL.
Dr. Sprung’s institution received funding from Data Safety and Monitoring Committee Asahi Kasei Pharma America Corporation (consultant), LeukoDx Ltd. (consultant), and from research study on biomarkers of sepsis, LeukoDx Ltd. (principal investigator). Dr. Sprung disclosed additional funding from International Sepsis Forum (board member) and disclosed: I was a member of the ACCP-SCCM Sepsis Definitions Conference Committee and The 2001 International Sepsis Definitions Conference Committee. Dr. Schein received funding from Josepher and Batteese (expert testimony, individual case medical legal), Peters and Monyak (expert testimony individual case medical legal) and from Florida Society of Critical Care Medicine (travel/accommodations/unrelated meeting expenses). He also disclosed: I was a member of the ACCP-SCCM Sepsis Definitions Conference Committee. His institution received funding from Asahi Kasei Pharma (clinical trial). Dr. Balk’s institution received funding from Ohio Medical (Quality Review Board). He received funding from bioMerieux (advisory board and lectures at CME event), bioMerieux (advisory board), and ThermoFisher Scientific (advisory board). Dr. Balk also disclosed: I was a member of the ACCP-SCCM Sepsis Definitions Conference Committee and The 2001 International Sepsis Definitions Conference Committee.
For information regarding this article, E-mail: email@example.com